• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Exelixis Inc. (Amendment)

    6/2/23 4:59:56 PM ET
    $EXEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $EXEL alert in real time by email
    SC 13D/A 1 exel_13a.htm






    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC  20549

    SCHEDULE 13D
    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*

    Exelixis, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.001 per share
    (Title of Class of Securities)
     
    30161Q104
    (Cusip Number)
     
    Hannah E. Dunn
    Farallon Capital Management, L.L.C.
    One Maritime Plaza, Suite 2100
    San Francisco, California 94111
    (415) 421-2132
    (Name, Address, and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     
    May 31, 2023
    (Date of Event which Requires Filing of this Statement)
     
    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [   ].
    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See Section 240.13d-7 for other parties to whom copies are to be sent.
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on following pages)
    Page 1 of 45 Pages



    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Capital Partners, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    WC
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    California
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    2,252,820
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    2,252,820
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,252,820
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    0.7%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN

    Page 2 of 45 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Capital Institutional Partners, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    WC
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    California
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    2,676,482
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    2,676,482
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,676,482
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    0.8%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN

    Page 3 of 45 Pages


    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Capital Institutional Partners II, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    WC
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    California
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    761,997
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    761,997
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    761,997
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    0.2%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN

    Page 4 of 45 Pages


    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Capital Institutional Partners III, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    WC
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    370,786
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    370,786
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    370,786
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    0.1%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN

    Page 5 of 45 Pages


    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Four Crossings Institutional Partners V, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    WC
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    487,247
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    487,247
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    487,247
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    0.1%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN

    Page 6 of 45 Pages


    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Capital Offshore Investors II, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    WC
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    4,608,927
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    4,608,927
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    4,608,927
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    1.4%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN

    Page 7 of 45 Pages


    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Capital (AM) Investors, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    WC
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    260,133
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    260,133
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    260,133
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    0.1%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN

    Page 8 of 45 Pages


    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Capital F5 Master I, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    WC
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    945,808
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    945,808
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    945,808
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    0.3%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN

    Page 9 of 45 Pages


    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Healthcare Partners Master, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    WC
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    13,495,800
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    13,495,800
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    13,495,800
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    4.1%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    PN

    Page 10 of 45 Pages


    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Partners, L.L.C.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    24,914,192
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    24,914,192
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    24,914,192
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.7%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    OO

    Page 11 of 45 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Institutional (GP) V, L.L.C.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    487,247
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    487,247
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    487,247
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    0.1%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    OO

    Page 12 of 45 Pages


    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon F5 (GP), L.L.C.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    945,808
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    945,808
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    945,808
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    0.3%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    OO

    Page 13 of 45 Pages


    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Farallon Healthcare Partners (GP), L.L.C.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    13,495,800
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    13,495,800
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    13,495,800
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    4.1%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    OO

    Page 14 of 45 Pages


    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Joshua J. Dapice
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    25,860,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    25,860,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    25,860,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.9%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    Page 15 of 45 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Philip D. Dreyfuss
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    25,860,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    25,860,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    25,860,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.9%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    Page 16 of 45 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Hannah E. Dunn
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    25,860,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    25,860,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    25,860,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.9%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    Page 17 of 45 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Michael B. Fisch
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    25,860,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    25,860,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    25,860,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.9%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    Page 18 of 45 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Richard B. Fried
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    25,860,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    25,860,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    25,860,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.9%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    Page 19 of 45 Pages


    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Varun N. Gehani
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    25,860,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    25,860,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    25,860,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.9%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    Page 20 of 45 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Nicolas Giauque
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    France
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    25,860,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    25,860,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    25,860,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.9%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    Page 21 of 45 Pages


    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    David T. Kim
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    25,860,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    25,860,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    25,860,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.9%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    Page 22 of 45 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Michael G. Linn
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    25,860,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    25,860,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    25,860,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.9%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    Page 23 of 45 Pages


    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Rajiv A. Patel
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    25,860,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    25,860,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    25,860,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.9%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    Page 24 of 45 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Thomas G. Roberts, Jr.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    25,860,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    25,860,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    25,860,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.9%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    Page 25 of 45 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Edric C. Saito
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    25,860,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    25,860,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    25,860,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.9%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN


    Page 26 of 45 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    William Seybold
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    25,860,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    25,860,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    25,860,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.9%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN


    Page 27 of 45 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Daniel S. Short
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    25,860,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    25,860,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    25,860,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.9%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN


    Page 28 of 45 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Andrew J. M. Spokes
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United Kingdom
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    25,860,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    25,860,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    25,860,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.9%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN


    Page 29 of 45 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    John R. Warren
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    25,860,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    25,860,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    25,860,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.9%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN


    Page 30 of 45 Pages

    13D
    CUSIP No. 30161Q104
     

    1
    NAMES OF REPORTING PERSONS
     
    Mark C. Wehrly
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)            
                                                                                                                                                      (a) [   ]
                                                                                                                                     (b) [X]**
    ** The reporting persons making this filing hold an aggregate of 25,860,000 Shares (as defined in Item 1), representing 7.9% of the class of securities outstanding.  The reporting person on this cover page, however, is a beneficial owner only of the securities reported by it on this cover page.
    3
    SEC USE ONLY
     
    4
    SOURCE OF FUNDS (See Instructions)
     
    N/A
    5
    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
    TO ITEMS 2(d) OR 2(e)
    [     ]
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
    0
    8
    SHARED VOTING POWER
     
    25,860,000
    9
    SOLE DISPOSITIVE POWER
     
    0
    10
    SHARED DISPOSITIVE POWER
     
    25,860,000
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    25,860,000
    12
    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
    CERTAIN SHARES (See Instructions)
                                                                                                                                                     [   ]
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
    7.9%
    14
    TYPE OF REPORTING PERSON (See Instructions)
     
    IN

    Page 31 of 45 Pages


    Preliminary Note: This Amendment No. 3 to Schedule 13D (this “Amendment”) amends and supplements the Schedule 13D initially filed on March 20, 2023, as amended and supplemented by Amendment No. 1 thereto filed on March 27, 2023, as amended and supplemented by Amendment No. 2 thereto filed on April 7, 2023 (the “Prior Schedule 13D” and, as amended and supplemented by this Amendment, this “Schedule 13D”).  Capitalized terms used without definition in this Amendment have the meanings ascribed thereto in the Prior Schedule 13D.

    Item 3. Source and Amount of Funds or Other Consideration

    This Amendment hereby amends and restates Item 3 of the Prior Schedule 13D in its entirety as follows:

    “The approximate net investment cost for the Shares held by each of the Farallon Funds is set forth below:

    Entity
    Number of Shares Held
     
    Approx. Net Investment Cost
     
    FCP
     
    2,252,820
    $
    38,780,455
    FCIP
     
    2,676,482
    $
    45,701,307
    FCIP II
     
    761,997
    $
    13,253,052
    FCIP III
     
    370,786
    $
    6,424,007
    FCIP V
     
    487,247
    $
    8,386,735
    FCOI II
     
    4,608,927
    $
    79,253,788
    FCAMI
     
    260,133
    $
    4,527,180
    F5MI
     
    945,808
    $
    16,407,083
    FHPM
    13,495,800
    $
    243,776,033
           
       
    $
    456,509,639

    The consideration for such acquisitions was obtained from working capital and/or from borrowings pursuant to margin accounts maintained by the Farallon Funds with one or more brokers in the ordinary course of business.  Such margin accounts from time to time may have debit balances secured by Shares. Since other securities may be held in such margin accounts, it may not be possible to determine the amount, if any, of margin borrowings used to acquire the Shares.”

    Page 32 of 45 Pages


    Item 4. Purpose of Transaction

    This Amendment hereby amends and supplements Item 4 of the Prior Schedule 13D by adding the following thereto:

    “On May 31, 2023, the three Farallon Nominees (Tomas J. Heyman, David E. Johnson, and Robert Oliver, Jr.) were elected to the Board at the 2023 Annual Meeting.  As a result, each of the Nomination Agreements terminated at such time in accordance with its terms.”

    Item 5. Interest in Securities of the Issuer

    This Amendment hereby amends and restates Item 5 of the Prior Schedule 13D in its entirety as follows:

    “
    The Farallon Funds

    (a),(b)
    The information set forth in Rows 7 through 13 of the cover page hereto for each Farallon Fund is incorporated herein by reference for each such Farallon Fund.  The percentage amount set forth in Row 13 for all cover pages filed herewith is calculated based upon the 325,636,738 Shares outstanding as of May 1, 2023, as reported by the Company in its Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on May 9, 2023.
     
    (c)
    The dates, number of Shares involved and the price per Share (excluding commissions) for all transactions in the Shares by the Farallon Funds since the filing of Amendment No. 2 to this Schedule 13D are set forth on Schedules A-I hereto and are incorporated herein by reference.  All of such transactions were open-market transactions.
     
    (d)
    The Farallon General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by the Farallon Funds other than F5MI.  The FCIP V General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by FCIP V.  The F5MI General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by F5MI.  The FHPM General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by FHPM.  Each of the Farallon Individual Reporting Persons is a managing member or senior managing member, as the case may be, of the Farallon General Partner and a manager or senior manager, as the case may be, of the FCIP V General Partner, the F5MI General Partner and the FHPM General Partner.
     
    (e)
    Not applicable.

    The Farallon General Partner

    (a),(b)
    The information set forth in Rows 7 through 13 of the cover page hereto for the Farallon General Partner is incorporated herein by reference.
     
    (c)
    None.
     
    (d)
    The Farallon General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by the Farallon Funds other than F5MI. Each of the Farallon Individual Reporting Persons is a managing member or senior managing member, as the case may be, of the Farallon General Partner.
     
    (e)
    Not applicable.

    Page 33 of 45 Pages


    The FCIP V General Partner

    (a),(b)
    The information set forth in Rows 7 through 13 of the cover page hereto for the FCIP V General Partner is incorporated herein by reference.
     
    (c)
    None.
     
    (d)
    The FCIP V General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by FCIP V. Each of the Farallon Individual Reporting Persons is a manager or senior manager, as the case may be, of the FCIP V General Partner.
     
    (e)
    Not applicable.

    The F5MI General Partner

    (a),(b)
    The information set forth in Rows 7 through 13 of the cover page hereto for the F5MI General Partner is incorporated herein by reference.
     
    (c)
    None.
     
    (d)
    The F5MI General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by F5MI. Each of the Farallon Individual Reporting Persons is a manager or senior manager, as the case may be, of the F5MI General Partner.
     
    (e)
    Not applicable.

    The FHPM General Partner

    (a),(b)
    The information set forth in Rows 7 through 13 of the cover page hereto for the FHPM General Partner is incorporated herein by reference.
     
    (c)
    None.
     
    (d)
    The FHPM General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by FHPM. Each of the Farallon Individual Reporting Persons is a manager or senior manager, as the case may be, of the FHPM General Partner.
     
    (e)
    Not applicable.

    The Farallon Individual Reporting Persons

    (a),(b)
    The information set forth in Rows 7 through 13 of the cover page hereto for each Farallon Individual Reporting Person is incorporated herein by reference for each such Farallon Individual Reporting Person.
     
    (c)
    None.
     
    (d)
    The Farallon General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by the Farallon Funds other than F5MI. The FCIP V General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by FCIP V. The F5MI General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by F5MI. The FHPM General Partner has the power to direct the receipt of dividends relating to, or the disposition of the proceeds of the sale of, the Shares held by FHPM. Each of the Farallon Individual Reporting Persons is a managing member or senior managing member, as the case may be, of the Farallon General Partner and a manager or senior manager, as the case may be, of the FCIP V General Partner, the F5MI General Partner and the FHPM General Partner.
     
    (e)
    Not applicable.

    Page 34 of 45 Pages


    The Shares reported hereby for the Farallon Funds are owned directly by the Farallon Funds. The Farallon General Partner, as general partner of FCP, FCIP, FCIP II, FCIP III, FCOI II and FCAMI and the sole member of the FCIP V General Partner and the FHPM General Partner, may be deemed to be a beneficial owner of all such Shares owned by the Farallon Funds other than F5MI. The FCIP V General Partner, as general partner of FCIP V, may be deemed to be a beneficial owner of all such Shares owned by FCIP V. The F5MI General Partner, as general partner of F5MI, may be deemed to be a beneficial owner of all such Shares owned by F5MI. The FHPM General Partner, as general partner of FHPM, may be deemed to be a beneficial owner of all such Shares owned by FHPM. Each of the Farallon Individual Reporting Persons, as a managing member or senior managing member, as the case may be, of the Farallon General Partner and a manager or senior manager, as the case may be, of the FCIP V General Partner, the F5MI General Partner and the FHPM General Partner, in each case with the power to exercise
    investment discretion, may be deemed to be a beneficial owner of all such Shares owned by the Farallon Funds. Each of the Farallon General Partner, the FCIP V General Partner, the F5MI General Partner, the FHPM General Partner and the Farallon Individual Reporting Persons hereby disclaims any beneficial ownership of any such Shares.

    As a result of the termination of the Nomination Agreement with Mr. David E. Johnson on May 31, 2023, the Reporting Persons are no longer deemed to be a “group” with Mr. Johnson and Caligan Partners LP (“Caligan”) for purposes of Section 13(d)(3) of the Exchange Act and Rule 13d-5(b)(1) promulgated thereunder.  For the avoidance of doubt, each of the Reporting Persons hereby disclaims any beneficial ownership of any Shares beneficially owned by Mr. Johnson and/or Caligan.”

    Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
    This Amendment hereby amends and supplements Item 6 of the Prior Schedule 13D by adding the following thereto:
    “As described in Item 4 above, as result of the election of each of the Farallon Nominees to the Board on May 31, 2023, each of the Nomination Agreements terminated at such time in accordance with its terms.”

    Page 35 of 45 Pages


    SIGNATURES
    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.
    Dated:  June 2, 2023
     
    /s/ Hannah E. Dunn
     
    FARALLON PARTNERS, L.L.C.,
     
    On its own behalf and
     
    As the General Partner of
     
    FARALLON CAPITAL PARTNERS, L.P.,
     
    FARALLON CAPITAL INSTITUTIONAL PARTNERS, L.P.,
     
    FARALLON CAPITAL INSTITUTIONAL PARTNERS II, L.P.,
     
    FARALLON CAPITAL INSTITUTIONAL PARTNERS III, L.P.,
     
    FARALLON CAPITAL OFFSHORE INVESTORS II, L.P. and
     
    FARALLON CAPITAL (AM) INVESTORS, L.P.
     
    By Hannah E. Dunn, Managing Member
       
     
    /s/ Hannah E. Dunn
     
    FARALLON INSTITUTIONAL (GP) V, L.L.C.
     
    On its own behalf and
     
    As the General Partner of
     
    FOUR CROSSINGS INSTITUTIONAL PARTNERS V, L.P.
     
    By Hannah E. Dunn, Manager
       
     
    /s/ Hannah E. Dunn
     
    FARALLON F5 (GP), L.L.C.
     
    On its own behalf and
     
    As the General Partner of
     
    FARALLON CAPITAL F5 MASTER I, L.P.
     
    By Hannah E. Dunn, Manager
       
     
    /s/ Hannah E. Dunn
     
    FARALLON HEALTHCARE PARTNERS (GP), L.L.C.
     
    On its own behalf and
     
    As the General Partner of
     
    FARALLON HEALTHCARE PARTNERS MASTER, L.P.
     
    By Hannah E. Dunn, Manager
       
     
    /s/ Hannah E. Dunn
     
    Hannah E. Dunn, individually and as attorney-in-fact for each of Joshua J. Dapice, Philip D. Dreyfuss, Michael B. Fisch, Richard B. Fried, Varun N. Gehani, Nicolas Giauque, David T. Kim, Michael G. Linn, Rajiv A. Patel, Thomas G. Roberts, Jr., Edric C. Saito, William Seybold, Daniel S. Short, Andrew J. M. Spokes, John R. Warren and Mark C. Wehrly

    The Powers of Attorney executed by each of Dapice, Dreyfuss, Fisch, Fried, Gehani, Giauque, Kim, Linn, Patel, Roberts, Saito, Seybold, Short, Spokes, Warren and Wehrly authorizing Dunn to sign and file this Schedule 13D on his behalf, which were filed as exhibits to the Schedule 13G filed with the SEC on January 31, 2023 by such Reporting Persons with respect to the Class A Ordinary Shares of ARYA Sciences Acquisition Corp IV, are hereby incorporated by reference.

    Page 36 of 45 Pages


    SCHEDULE A

    FARALLON CAPITAL PARTNERS, L.P.

    This Schedule sets forth information with respect to each purchase and sale of Shares effectuated by the Reporting Person since the filing of Amendment No. 2 to this Schedule 13D. Unless otherwise indicated, all transactions were effectuated in the open market through a broker.

    TRADE DATE
    NO. OF SHARES PURCHASED (P) OR SOLD (S)
    PRICE PER SHARE ($)
    5/9/2023
    15,500 (P)
    $19.29
    5/10/2023
    44,400 (P)
    $19.10
    5/11/2023
    17,600 (P)
    $19.35
    5/12/2023
    18,200 (P)
    $19.29
    5/15/2023
    17,600 (P)
    $19.55
    5/16/2023
    23,300 (P)
    $19.26
    5/17/2023
    17,300 (P)
    $19.25
    5/18/2023
    21,100 (P)
    $19.67
    5/19/2023
    19,800 (P)
    $19.85
    5/22/2023
    33,500 (P)
    $19.86
    5/24/2023
    22,100 (P)
    $19.32
    5/24/2023
    5,400 (P)
    $19.37
    5/25/2023
    5,300 (P)
    $19.05
    5/31/2023
    3,400 (P)
    $19.32
    5/31/2023
    9,400 (P)
    $19.13
    6/1/2023
    19,300 (P)
    $19.43


    Page 37 of 45 Pages


    SCHEDULE B

    FARALLON CAPITAL INSTITUTIONAL PARTNERS, L.P.

    This Schedule sets forth information with respect to each purchase and sale of Shares effectuated by the Reporting Person since the filing of Amendment No. 2 to this Schedule 13D. Unless otherwise indicated, all transactions were effectuated in the open market through a broker.

    TRADE DATE
    NO. OF SHARES PURCHASED (P) OR SOLD (S)
    PRICE PER SHARE ($)
    5/9/2023
    10,700 (P)
    $19.29
    5/10/2023
    31,600 (P)
    $19.10
    5/11/2023
    12,000 (P)
    $19.35
    5/12/2023
    12,900 (P)
    $19.29
    5/15/2023
    12,700 (P)
    $19.55
    5/16/2023
    17,500 (P)
    $19.26
    5/17/2023
    12,800 (P)
    $19.25
    5/18/2023
    16,100 (P)
    $19.67
    5/19/2023
    17,100 (P)
    $19.85
    5/22/2023
    29,300 (P)
    $19.86
    5/24/2023
    17,100 (P)
    $19.32
    5/24/2023
    4,200 (P)
    $19.37
    5/25/2023
    4,200 (P)
    $19.05
    5/31/2023
    2,900 (P)
    $19.32
    5/31/2023
    8,000 (P)
    $19.13
    6/1/2023
    16,500 (P)
    $19.43


    Page 38 of 45 Pages


    SCHEDULE C

    FARALLON CAPITAL INSTITUTIONAL PARTNERS II, L.P.

    This Schedule sets forth information with respect to each purchase and sale of Shares effectuated by the Reporting Person since the filing of Amendment No. 2 to this Schedule 13D. Unless otherwise indicated, all transactions were effectuated in the open market through a broker.

    TRADE DATE
    NO. OF SHARES PURCHASED (P) OR SOLD (S)
    PRICE PER SHARE ($)
    5/9/2023
    6,700 (P)
    $19.29
    5/10/2023
    18,900 (P)
    $19.10
    5/11/2023
    6,500 (P)
    $19.35
    5/12/2023
    6,700 (P)
    $19.29
    5/15/2023
    6,600 (P)
    $19.55
    5/16/2023
    9,000 (P)
    $19.26
    5/17/2023
    6,400 (P)
    $19.25
    5/18/2023
    7,900 (P)
    $19.67
    5/19/2023
    7,700 (P)
    $19.85
    5/22/2023
    13,100 (P)
    $19.86
    5/24/2023
    7,900 (P)
    $19.32
    5/24/2023
    1,900 (P)
    $19.37
    5/25/2023
    1,900 (P)
    $19.05
    5/31/2023
    1,200 (P)
    $19.32
    5/31/2023
    3,400 (P)
    $19.13
    6/1/2023
    7,000 (P)
    $19.43


    Page 39 of 45 Pages


    SCHEDULE D

    FARALLON CAPITAL INSTITUTIONAL PARTNERS III, L.P.

    This Schedule sets forth information with respect to each purchase and sale of Shares effectuated by the Reporting Person since the filing of Amendment No. 2 to this Schedule 13D. Unless otherwise indicated, all transactions were effectuated in the open market through a broker.

    TRADE DATE
    NO. OF SHARES PURCHASED (P) OR SOLD (S)
    PRICE PER SHARE ($)
    5/9/2023
    2,000 (P)
    $19.29
    5/10/2023
    5,500 (P)
    $19.10
    5/11/2023
    2,100 (P)
    $19.35
    5/12/2023
    2,200 (P)
    $19.29
    5/15/2023
    2,200 (P)
    $19.55
    5/16/2023
    2,900 (P)
    $19.26
    5/17/2023
    2,200 (P)
    $19.25
    5/18/2023
    2,700 (P)
    $19.67
    5/19/2023
    2,800 (P)
    $19.85
    5/22/2023
    4,900 (P)
    $19.86
    5/24/2023
    2,900 (P)
    $19.32
    5/24/2023
    700 (P)
    $19.37
    5/25/2023
    700 (P)
    $19.05
    5/31/2023
    500 (P)
    $19.32
    5/31/2023
    1,200 (P)
    $19.13
    6/1/2023
    2,700 (P)
    $19.43


    Page 40 of 45 Pages


    SCHEDULE E

    FOUR CROSSINGS INSTITUTIONAL PARTNERS V, L.P.

    This Schedule sets forth information with respect to each purchase and sale of Shares effectuated by the Reporting Person since the filing of Amendment No. 2 to this Schedule 13D. Unless otherwise indicated, all transactions were effectuated in the open market through a broker.

    TRADE DATE
    NO. OF SHARES PURCHASED (P) OR SOLD (S)
    PRICE PER SHARE ($)
    5/9/2023
    2,200 (P)
    $19.29
    5/10/2023
    6,100 (P)
    $19.10
    5/11/2023
    2,400 (P)
    $19.35
    5/12/2023
    2,600 (P)
    $19.29
    5/15/2023
    2,500 (P)
    $19.55
    5/16/2023
    3,400 (P)
    $19.26
    5/17/2023
    2,600 (P)
    $19.25
    5/18/2023
    3,200 (P)
    $19.67
    5/19/2023
    3,500 (P)
    $19.85
    5/22/2023
    5,900 (P)
    $19.86
    5/24/2023
    3,400 (P)
    $19.32
    5/24/2023
    800 (P)
    $19.37
    5/25/2023
    800 (P)
    $19.05
    5/31/2023
    600 (P)
    $19.32
    5/31/2023
    1,600 (P)
    $19.13
    6/1/2023
    3,300 (P)
    $19.43


    Page 41 of 45 Pages


    SCHEDULE F

    FARALLON CAPITAL OFFSHORE INVESTORS II, L.P.

    This Schedule sets forth information with respect to each purchase and sale of Shares effectuated by the Reporting Person since the filing of Amendment No. 2 to this Schedule 13D. Unless otherwise indicated, all transactions were effectuated in the open market through a broker.

    TRADE DATE
    NO. OF SHARES PURCHASED (P) OR SOLD (S)
    PRICE PER SHARE ($)
    5/9/2023
    28,600 (P)
    $19.29
    5/10/2023
    82,632 (P)
    $19.10
    5/11/2023
    32,768 (P)
    $19.35
    5/12/2023
    33,805 (P)
    $19.29
    5/15/2023
    33,100 (P)
    $19.55
    5/16/2023
    44,059 (P)
    $19.26
    5/17/2023
    32,736 (P)
    $19.25
    5/18/2023
    40,000 (P)
    $19.67
    5/19/2023
    36,600 (P)
    $19.85
    5/22/2023
    62,200 (P)
    $19.86
    5/24/2023
    41,400 (P)
    $19.32
    5/24/2023
    10,100 (P)
    $19.37
    5/25/2023
    10,100 (P)
    $19.05
    5/31/2023
    6,530 (P)
    $19.32
    5/31/2023
    17,800 (P)
    $19.13
    6/1/2023
    36,970 (P)
    $19.43


    Page 42 of 45 Pages


    SCHEDULE G

    FARALLON CAPITAL (AM) INVESTORS, L.P.

    This Schedule sets forth information with respect to each purchase and sale of Shares effectuated by the Reporting Person since the filing of Amendment No. 2 to this Schedule 13D. Unless otherwise indicated, all transactions were effectuated in the open market through a broker.

    TRADE DATE
    NO. OF SHARES PURCHASED (P) OR SOLD (S)
    PRICE PER SHARE ($)
    5/9/2023
    2,200 (P)
    $19.29
    5/10/2023
    6,500 (P)
    $19.10
    5/11/2023
    2,500 (P)
    $19.35
    5/12/2023
    2,600 (P)
    $19.29
    5/15/2023
    2,500 (P)
    $19.55
    5/16/2023
    3,300 (P)
    $19.26
    5/17/2023
    2,500 (P)
    $19.25
    5/18/2023
    3,000 (P)
    $19.67
    5/19/2023
    2,800 (P)
    $19.85
    5/22/2023
    4,700 (P)
    $19.86
    5/24/2023
    3,000 (P)
    $19.32
    5/24/2023
    700 (P)
    $19.37
    5/25/2023
    700 (P)
    $19.05
    5/31/2023
    500 (P)
    $19.32
    5/31/2023
    1,200 (P)
    $19.13
    6/1/2023
    2,600 (P)
    $19.43

    Page 43 of 45 Pages


    SCHEDULE H

    FARALLON CAPITAL F5 MASTER, L.P.

    This Schedule sets forth information with respect to each purchase and sale of Shares effectuated by the Reporting Person since the filing of Amendment No. 2 to this Schedule 13D. Unless otherwise indicated, all transactions were effectuated in the open market through a broker.

    TRADE DATE
    NO. OF SHARES PURCHASED (P) OR SOLD (S)
    PRICE PER SHARE ($)
    5/9/2023
    5,300 (P)
    $19.29
    5/10/2023
    15,200 (P)
    $19.10
    5/11/2023
    6,100 (P)
    $19.35
    5/12/2023
    6,300 (P)
    $19.29
    5/15/2023
    6,100 (P)
    $19.55
    5/16/2023
    8,300 (P)
    $19.26
    5/17/2023
    6,100 (P)
    $19.25
    5/18/2023
    7,600 (P)
    $19.67
    5/19/2023
    6,400 (P)
    $19.85
    5/22/2023
    11,100 (P)
    $19.86
    5/24/2023
    7,200 (P)
    $19.32
    5/24/2023
    1,700 (P)
    $19.37
    5/25/2023
    1,800 (P)
    $19.05
    5/31/2023
    1,200 (P)
    $19.32
    5/31/2023
    3,200 (P)
    $19.13
    6/1/2023
    7,000 (P)
    $19.43


    Page 44 of 45 Pages


    SCHEDULE I

    FARALLON HEALTHCARE PARTNERS MASTER, L.P.

    This Schedule sets forth information with respect to each purchase and sale of Shares effectuated by the Reporting Person since the filing of Amendment No. 2 to this Schedule 13D. Unless otherwise indicated, all transactions were effectuated in the open market through a broker.

    TRADE DATE
    NO. OF SHARES PURCHASED (P) OR SOLD (S)
    PRICE PER SHARE ($)
    5/9/2023
    52,200 (P)
    $19.30
    5/10/2023
    150,372 (P)
    $19.11
    5/11/2023
    58,428 (P)
    $19.34
    5/12/2023
    60,865 (P)
    $19.23
    5/15/2023
    59,400 (P)
    $19.55
    5/16/2023
    79,810 (P)
    $19.26
    5/17/2023
    58,925 (P)
    $19.25
    5/18/2023
    72,500 (P)
    $19.68
    5/19/2023
    69,100 (P)
    $19.85
    5/22/2023
    117,400 (P)
    $19.86
    5/24/2023
    70,000 (P)
    $19.32
    5/24/2023
    17,000 (P)
    $19.37
    5/25/2023
    17,000 (P)
    $19.05
    5/31/2023
    11,175 (P)
    $19.32
    5/31/2023
    20,000 (P)
    $19.13
    5/31/2023
    10,500 (P)
    $19.09
    6/1/2023
    63,325 (P)
    $19.43


    Page 45 of 45 Pages
    Get the next $EXEL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EXEL

    DatePrice TargetRatingAnalyst
    2/24/2025$36.00Overweight → Equal Weight
    Wells Fargo
    1/27/2025$30.00 → $40.00Equal-Weight → Overweight
    Morgan Stanley
    1/24/2025Outperform → Perform
    Oppenheimer
    12/20/2024$36.00 → $40.00Outperform → Market Perform
    BMO Capital Markets
    12/17/2024$35.00 → $39.00Buy → Neutral
    BofA Securities
    10/16/2024$30.00 → $34.00Outperform
    RBC Capital Mkts
    9/19/2024$30.00Neutral
    UBS
    4/11/2024$25.00Overweight → Equal Weight
    Barclays
    More analyst ratings

    $EXEL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025

      – Zanzalintinib in combination with nivolumab demonstrated an objective response rate of 63% and a disease control rate of 90% – – Additional results from dose-finding cohorts will also be presented – Exelixis, Inc. (NASDAQ:EXEL) today announced results from an expansion cohort of the phase 1b/2 STELLAR-002 trial evaluating zanzalintinib in combination with either nivolumab (Opdivo®) or a fixed-dose combination of nivolumab and relatlimab (Opdualag™) in patients with previously untreated advanced clear cell renal cell carcinoma (RCC). These findings, as well as data from multiple dose-escalation cohorts from STELLAR-002, will be presented at the 2025 American Society of Clinical Oncology

      5/22/25 5:17:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June

      - Presentations to be webcast on www.exelixis.com - Exelixis, Inc. (NASDAQ:EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May and June: TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA: Exelixis is scheduled to present virtually at 2:30 p.m. ET / 11:30 a.m. PT on Tuesday, May 27. William Blair 45th Annual Growth Stock Conference: Exelixis is scheduled to present at 11:00 a.m. ET / 10:00 a.m. CT / 8:00 a.m. PT on Tuesday, June 3 in Chicago. Jefferies Global Healthcare Conference 2025: Exelixis is scheduled to present at 7:35 a.m. ET / 4:35 a.m. PT on Wednesday, June 4 in New York City.

      5/22/25 4:05:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Invenra Highlights Exelixis' Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors

      Invenra Inc., a biotechnology company specializing in the discovery and development of multispecific antibodies, today announced that its collaboration partner, Exelixis, Inc. (NASDAQ:EXEL), has initiated the dose-escalation stage of the first-in-human Phase 1 clinical study of XB628 in participants with recurrent advanced or metastatic solid tumors. XB628 is a first-in-class bispecific antibody natural killer (NK) cell engager that targets NK group 2 member A (NKG2A), an inhibitory receptor on NK cells, and programmed cell death-ligand 1 (PD-L1). The molecule was discovered in part through a collaboration between Exelixis and Invenra. About Invenra Inc. Invenra Inc. pioneers the discove

      5/13/25 6:06:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Exelixis downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Exelixis from Overweight to Equal Weight and set a new price target of $36.00

      2/24/25 7:08:46 AM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exelixis upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Exelixis from Equal-Weight to Overweight and set a new price target of $40.00 from $30.00 previously

      1/27/25 7:40:23 AM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exelixis downgraded by Oppenheimer

      Oppenheimer downgraded Exelixis from Outperform to Perform

      1/24/25 7:28:21 AM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Exelixis Inc. (Amendment)

      SC 13D/A - EXELIXIS, INC. (0000939767) (Subject)

      5/8/24 4:11:20 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Exelixis Inc.

      SC 13G - EXELIXIS, INC. (0000939767) (Subject)

      2/13/24 9:19:48 AM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Exelixis Inc. (Amendment)

      SC 13D/A - EXELIXIS, INC. (0000939767) (Subject)

      6/2/23 5:05:24 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXEL
    SEC Filings

    See more
    • SEC Form 144 filed by Exelixis Inc.

      144 - EXELIXIS, INC. (0000939767) (Subject)

      5/20/25 5:23:50 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Exelixis Inc.

      144 - EXELIXIS, INC. (0000939767) (Subject)

      5/15/25 4:05:42 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Exelixis Inc.

      10-Q - EXELIXIS, INC. (0000939767) (Filer)

      5/13/25 4:14:27 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Johnson David Edward bought $8,733,955 worth of shares (425,000 units at $20.55) (SEC Form 4)

      4 - EXELIXIS, INC. (0000939767) (Issuer)

      5/30/24 7:50:14 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Johnson David Edward bought $3,932,734 worth of shares (190,000 units at $20.70) (SEC Form 4)

      4 - EXELIXIS, INC. (0000939767) (Issuer)

      2/22/24 5:08:50 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Johnson David Edward sold $2,602,038 worth of shares (120,409 units at $21.61) and bought $2,602,038 worth of shares (120,409 units at $21.61) (SEC Form 4)

      4 - EXELIXIS, INC. (0000939767) (Issuer)

      11/29/23 4:30:29 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXEL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for CABOMETYX issued to EXELIXIS INC

      Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-16) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 09/20/2023. Application Category: NDA, Application Number: 208692, Application Classification: Labeling

      9/21/23 4:37:02 AM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for CABOMETYX issued to EXELIXIS INC

      Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-14) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 07/14/2022. Application Category: NDA, Application Number: 208692, Application Classification: Efficacy

      7/15/22 4:38:40 AM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for CABOMETYX issued to EXELIXIS INC

      Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-12) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 09/17/2021. Application Category: NDA, Application Number: 208692, Application Classification: Efficacy

      9/20/21 3:53:29 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXEL
    Financials

    Live finance-specific insights

    See more
    • Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update

      - Total Revenues of $555.4 million, Cabozantinib Franchise U.S. Net Product Revenues of $513.3 million - - GAAP Diluted EPS of $0.55, Non-GAAP Diluted EPS of $0.62 - - Increasing 2025 Full Year Net Product Revenues and Total Revenues Guidance by $100 million - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the first quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. "Exelixis delivered outstanding financial performance in the first quarter of 2025, driven by accelerating growth in CABOMETYX® d

      5/13/25 4:07:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025

      – Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its first quarter 2025 financial results will be released on Tuesday, May 13, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the Event

      4/29/25 4:05:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update

      - Total Revenues of $567 million for the Fourth Quarter of 2024, $2.17 billion for the Fiscal Year 2024 - - Cabozantinib Franchise Achieved $1.81 billion in U.S. Net Product Revenues for the Fiscal Year 2024, including $515 million for the Fourth Quarter of 2024 - - GAAP Diluted EPS of $0.48 for the Fourth Quarter of 2024, $1.76 for the Fiscal Year 2024 - - Non-GAAP Diluted EPS of $0.55 for the Fourth Quarter of 2024, $2.00 for the Fiscal Year 2024 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key corporate objectiv

      2/11/25 4:05:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXEL
    Leadership Updates

    Live Leadership Updates

    See more
    • ONCOLOGY COMMERCIALIZATION LEADER P.J. HALEY TO JOIN NETRAMARK BOARD OF DIRECTORS

      TORONTO, Oct. 9, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE:AIAI) (OTCQB:AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, is pleased to announce the appointment of P.J. Haley, Executive Vice President, Commercial at Exelixis, Inc. (NASDAQ:EXEL), as a director of the Company, effective October 15th, 2024. Mr. Haley will be replacing Sheetal Jaitly, who is stepping down as a director after a period of dedicated service and contributions to the Company. As NetraMark focuses on advancing its technology for late phas

      10/9/24 8:30:00 AM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024

      – Cabozantinib franchise achieves approximately $1.630 billion in preliminary U.S. net product revenues for fiscal year 2023 – – Fiscal year 2024 net product revenues guidance of $1,650 million - $1,750 million; 2024 R&D expense guidance of $925 million - $975 million – – Appointment of two new board members, Mary C. Beckerle, Ph.D., and Gail Eckhardt, M.D., with extensive drug development and corporate governance expertise – – Implementing corporate restructuring to focus R&D resources on clinical stage and IND-enabling activities to maximize pipeline success and operational efficiency – – Board of Directors authorized $450 million share repurchase in 2024 after successful completi

      1/7/24 4:00:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer

      -- Dr. Peterson's extensive experience includes clinical development, medical affairs, and regulatory leadership in support of innovative oncology product portfolios -- Exelixis, Inc. (NASDAQ:EXEL) today announced it has appointed Amy Peterson, M.D., its next Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer. Dr. Peterson is a veteran oncology drug development leader whose experience includes senior clinical development and operational roles at Genentech, Medivation, BeiGene and CytomX. She joins Exelixis as the company accelerates development of its product pipeline and builds on the success of its global cabozantinib oncology franchise. "With a

      8/23/23 4:30:00 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Commercial Haley Patrick J. sold $1,515,091 worth of shares (34,387 units at $44.06), decreasing direct ownership by 8% to 412,072 units (SEC Form 4)

      4 - EXELIXIS, INC. (0000939767) (Issuer)

      5/22/25 7:25:20 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Heyman Tomas J. sold $201,254 worth of shares (4,544 units at $44.29), decreasing direct ownership by 12% to 32,470 units (SEC Form 4)

      4 - EXELIXIS, INC. (0000939767) (Issuer)

      5/22/25 7:25:09 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Poste George exercised 20,634 shares at a strike of $19.77 and sold $948,958 worth of shares (20,634 units at $45.99) (SEC Form 4)

      4 - EXELIXIS, INC. (0000939767) (Issuer)

      5/16/25 8:58:27 PM ET
      $EXEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care